Navigation Links
LSUHSC researcher awarded NCI grant to study link between chronic inflammation and cancer
Date:7/18/2013

New Orleans, LA Yan Cui, PhD, Associate Professor of Microbiology, Immunology, & Parasitology at LSU Health Sciences Center New Orleans and the LSUHSC Stanley S. Scott Cancer Center, has been awarded a $1.5 million grant over five years by the National Cancer Institute to study the role of chronic inflammation in the development and progression of cancer.

Tumor suppressor protein 53, or p53, is a crucial molecule that is known to prevent cancer by either directly killing cancer cells or by stopping cancer cells from multiplying. The loss of p53 function resulting from genetic changes is detected in 50% of tumors and is considered to be one of the leading causes of cancer. However, p53 dysfunction caused by these mutations can also occur in normal cells surrounding the cancer cells, called stromal cells, and mutations in the p53 gene in some of them are associated with increased cancer spread and poor prognosis. According to the National Cancer Institute, a stromal cell is a type of cell that makes up certain types of connective tissue (supporting tissue that surrounds other tissues and organs). When cells become malignant, the surrounding stromal cells also change. So far, it is not entirely clear how these adjacent, normal cells that lack functional p53 affect the growth and replication of cancer cells.

This grant award is based upon published studies performed in Dr. Cui's laboratory, one of which was chronicled as a cover story in the March 15, 2013, issue of Cancer Research.

These studies demonstrated that a lack of functional p53 in tumor-associated stromal cells, as well as some of the immune cells, leads to an inflammatory microenvironment that suppresses the body's immune system to fight the cancer, increases the number of stromal cells infiltrating the tumor, and promotes blood vessel formation to nourish the tumor leading to its accelerated growth.

"These earlier findings broaden our understanding of the importance of this critical tumor suppressor protein as a guardian and gatekeeper for the proper function of patients' immune systems," notes Dr. Cui. "This newly funded project will further investigate whether hindering p53 causes chronic inflammation that creates an environment conducive for cancer formation, growth, and metastasis."

Dr. Cui will collaborate with Augusto Ochoa, MD, Director of the LSUHSC Stanley S. Scott Cancer Center, and Paulo Rodriguez, PhD, an assistant professor at LSU Health Sciences Center New Orleans, both leaders in the field of inflammatory cells and cancer. The long-term goal is to develop new approaches that target the p53 pathway and tumor-associated stromal cells to prevent or advance the treatment of cancer.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC research identifies new risk factors for parasitic infection
2. LSUHSC research discovers new drug target for metastatic breast cancer
3. LSUHSC research identifies co-factors critical to PTSD development
4. LSUHSC scientist awarded nearly $2 million to determine role of biofilms in common fungal infection
5. LSUHSC research discovery provides therapeutic target for ALS
6. LSUHSCs Weiss chosen to help set national eye policy, research
7. LSUHSC research identifies new therapeutic target for Alzheimers disease
8. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
9. LSUHSC research finds treating stress prevented new MS brain lesions
10. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
11. Solving DNA puzzles is overwhelming computer systems, researchers warn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology: